0001104659-24-030201.txt : 20240304 0001104659-24-030201.hdr.sgml : 20240304 20240304060538 ACCESSION NUMBER: 0001104659-24-030201 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240229 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 24712746 BUSINESS ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 230 PARK AVENUE STREET 2: SUITE 3350 CITY: NEW YORK STATE: NY ZIP: 10169 8-K 1 tm247768d1_8k.htm FORM 8-K
false 0001722964 0001722964 2024-02-29 2024-02-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 29, 2024

 

Y-MABS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38650   47-4619612

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

230 Park Avenue

Suite 3350

New York, New York 10169

(Address of principal executive offices) (Zip Code)

 

(646) 885-8505

(Registrant’s telephone number, include area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock, $0.0001 par value   YMAB   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 29, 2024, the Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. (the “Company”) increased the size of the Board from eight to nine directors and elected Mary A. Tagliaferri, M.D., to serve as a Class I director of the Company, in each case effective as of such date. Dr. Tagliaferri’s term as a Class I director continues until the Company’s 2025 annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.

 

Dr. Tagliaferri, 58, has a highly accomplished biotechnology career and is currently the Chief Medical Officer and Senior Vice President of Nektar Therapeutics. Nektar is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. At Nektar, since joining the company in 2015, Dr. Tagliaferri has been responsible for numerous clinical studies evaluating novel therapeutics in oncology and she was also instrumental in establishing key strategic partnerships. Previously, she served as Chief Medical Officer and Chief Regulatory Officer for Kanglaite-USA and was Co-Founder, President and Board Member of Bionovo, Inc. Dr. Tagliaferri currently serves on the board of Enzo Biochem, Inc. and she served on the board of RayzeBio, Inc from 2021 until the acquisition by Bristol-Myers Squibb Company in 2024. She earned her Bachelor of Science degree at Cornell University and her medical degree at the University of California, San Francisco. Dr. Tagliaferri was honored as an Eminent Woman Leader in Healthcare by Inc Magazine in 2023. She was named to the Women who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019. Dr. Tagliaferri was also recognized as Woman of the Year in 2012 by the State of California, Assembly District 14. She has been lead author or contributor to approximately 90 peer-reviewed journal publications.

 

Dr. Tagliaferri will receive cash and equity compensation for her service on the Board in accordance with the Company’s Director Compensation Policy described under “Director Compensation” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2023, which Director Compensation Policy was filed by the Company as Exhibit 10.41 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 30, 2023.

 

In connection with her election to the Board, the Company and Dr. Tagliaferri entered into the Company’s standard form indemnification agreement, previously adopted and disclosed by the Company and filed as Exhibit 10.11 to the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 24, 2018. The indemnification agreement, among other things, requires the Company to indemnify Dr. Tagliaferri for certain expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by her in any action or proceeding arising out of her services as a director of the Company or any other entity or enterprise to which she provides services at the Company’s request.

 

Item 7.01 Regulation FD Disclosure.

 

On March 4, 2024, the Company issued a press release announcing the election of Dr. Tagliaferri to the Board. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

 

The information furnished pursuant to Item 7.01 of this Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No.		 Description
99.1 Press Release dated March 4, 2024
104 Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Y-MABS THERAPEUTICS, INC.
     
Date: March 4, 2024 By: /s/ Michael Rossi
    Michael Rossi
    President and Chief Executive Officer

 

 

 

 

 

 EX-99.1 2 tm247768d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

 

Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development

 

New York, NY, March 4, 2024 – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Mary Tagliaferri, M.D. to the Company’s Board of Directors effective February 29, 2024. Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors.

 

“We are thrilled to welcome Mary to our Board of Directors during such an exciting time for Y-mAbs,” said Michael Rossi, President and Chief Executive Officer. “Her extensive industry leadership experience and expertise in developing cancer therapies will be invaluable as we continue to advance our novel Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (“SADA PRIT”) technology platform and our lead clinical programs.”

 

“Y-mAbs’ highly differentiated SADA PRIT technology platform is exciting,” said Dr. Tagliaferri. “I am impressed by Y-mAbs’ management team, innovation and capabilities, commercial success and financial position. I look forward to working alongside members of this distinguished Board and contributing as the Company continues to advance novel oncology therapies to potentially improve patient lives.”

 

Dr. Tagliaferri has a highly accomplished biotechnology career and is currently the Chief Medical Officer and Senior Vice President of Nektar Therapeutics. Nektar is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing innovative medicines in the field of immunotherapy. At Nektar, Dr. Tagliaferri has been responsible for numerous clinical studies evaluating novel therapeutics in oncology and she was also instrumental in establishing key strategic partnerships. Previously, she served as Chief Medical Officer for KangLaiTe-USA and was Co-Founder, President and Board Member of Bionovo, Inc. Dr. Tagliaferri currently serves on the board of Enzo Biochem, Inc. and she served on the board of RayzeBio, Inc. from 2021 until the acquisition by Bristol-Myers Squibb in 2024. She earned her Bachelor of Science degree at Cornell University and her medical degree at the University of California, San Francisco.

 

Dr. Tagliaferri was honored as an Eminent Woman Leader in Healthcare by Inc Magazine in 2023. She was named to the Women who Lead in Life Sciences and Most Influential Women in Business lists by the San Francisco Business Times in 2019. Dr. Tagliaferri was also recognized as Woman of the Year in 2012 by the State of California, Assembly District 14. She has been lead author or contributor to approximately 90 peer-reviewed journal publications.

 

About Y-mAbs

 

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

 

 

 

 

 

Forward-Looking Statements

 

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; the Company’s plans and strategies, development, commercialization and product distribution plans; expectations with respect to the Company’s products and product candidates, including potential benefits thereof, and the potential of the SADA Technology and potential benefits and applications thereof; statements with respect to SADA as a differentiated radioimmunotherapy platform; expectations relating to the SADA Technology, including expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs; expectations that the Company will continue to advance novel oncology therapies and its lead clinical programs to potentially improve patient lives;; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; the risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture; the Company’s inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

 

DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.

 

Investor Contact:  
   
Courtney Dugan  
VP, Head of Investor Relations  
cdu@ymabs.com  

 

 

 

 EX-101.SCH 3 ymab-20240229.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ymab-20240229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ymab-20240229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm247768d1_ex99-1img001.jpg GRAPHIC begin 644 tm247768d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 29, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 29, 2024
Entity File Number 001-38650
Entity Registrant Name Y-MABS THERAPEUTICS, INC.
Entity Central Index Key 0001722964
Entity Tax Identification Number 47-4619612
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 230 Park Avenue
Entity Address, Address Line Two Suite 3350
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10169
City Area Code 646
Local Phone Number 885-8505
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol YMAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://ymabs.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm247768d1_8k.htm ymab-20240229.xsd ymab-20240229_lab.xml ymab-20240229_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm247768d1_8k.htm": { "nsprefix": "ymab", "nsuri": "http://ymabs.com/20240229", "dts": { "inline": { "local": [ "tm247768d1_8k.htm" ] }, "schema": { "local": [ "ymab-20240229.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ymab-20240229_lab.xml" ] }, "presentationLink": { "local": [ "ymab-20240229_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://ymabs.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247768d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm247768d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ymabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-030201-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-030201-xbrl.zip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

8YK(I M=@6<06UH9T)B:U; /BFN1G.Q3 KX1*CG\.&5S'JP&]@#QVQ8"85R6%<9HV#\292(VY)0>Z)Y2?W5D.=%&2 MUS)>$ JBBTBE=-JMFN,2BY@R)?0DK<]#3G$5X=#1G09-Z;S'YSIE[R VL-"M M8^+C'S*?GDM]H_H_7X^"3][3!M,_I:A' &PY!P;GO6 ')XD>(2B8.]."K>&W M3G$N+(]IZ[DO/W"OO:Z'EB34: >T^4 MB II ([Q6P0ACF04,X\L I-)^Q=SBE;7^"Z*2.Z,^,)1U]@%L\UQ*?2XO74D M01M\DVZ]CD,B3]04_B6DA]RP$HGZYQQV:'%1T#)V!J.$]!>+B:#60AQX#& - MK>1:(BX LYQ:"K\P^<&7&ZM6,N:'!*[P@.QL!N.Q% PHDN557 Y?GV3P8!C= M/XD"<)W$Y$5K,95 M"NGQ?F;X/CKO7$]4K>>0$R^,\[AVDI8AV81=M/:H=!1T')*-0UD3A?BZI,?% MFB!BIGCO17=UT8BIB@Y43T]S_3[X=) +9U@4!$K:ZK!GS<4>H6+5JMI($)DW M]F+ONR"O)M01A!.R]#,R[(H"J:5/H4?=@[)? M@0)S @PE E?,@../494<'8XB4_H*1WVFIM\G'UA5@-I]4('?D4JARX\J\'N? M4.%714Q=Z \(,:R6XZ"C!BJ:'2).2R!(ZK^AU$$"U%,F1&XJ9=JU2E.F/%+? M7-8 O-[)60OR)>G54%^I(\!?U6#ZSN9%9$U M,@EB"X VJ:4C"EVH-$0Q%@:+#Z_Y/XV>BIGL\>O7FY/Q?HX/KGR\/GU@U MA5G1K^*;7+[37F8RZD_?3F^_[570QR)>G8Y'?79<2IY-GX410(60J<+T,\28 M5!9L(1:_3ZRD6AH(DD!F']GR5N2JM"9*)1)G)FN %1'KV,(_8:K6W LY\00D M&:E0G*P@%) @(CL?7W_&!P8ZBO"=@ADQFK?:U 7P_,O.?_51?^KWQ2E!S7UQ M"3\<8OW;DC('CA7]?C5;.1B?_5+?&4[J>U-@R3-J:5=/(N,AWWWQ/;>YC47R M:YX=I=1=W?ZYHV MG(8%_5O0YA XF[F0(V^],U$H^H@]=-:&8LKZCX8I:0JPV1*YG0EE5W4JC=Y MU:'_852#8#PO+3>TQ"CF1L7>B^?/JU9&>\O>2<>6DW?Q#,4P1+383-"8VL>N M+6/.SCT!1-RPG.I,>^Y.]ZCSE&J5U-U=5D6G\#@[LU9J:M:@4515"[WJ6MI6 MI6E6%N5)W $=$E3C]@ZNF!J4"\/.V<="WW4G@4RMA0)[ZQ P8*$:IB1<-U#' M#C?R<4/1MJDU^CK)J$<_[9.!%A.=@*@E=INF'J0!X#4A!LD@E9GT>#N=WRQJ M]$HMUYM%MY7O:18U!S$0*XJF4*E/'K8UML)0U<_EUMMRI[<+(==P<$5(!+/" M,,)TT=L6P(/"Y6JLZJB$;FTPIJ8C%82K^FLMJEILJVJI.W3MUAKCQ+J-O\(% MNSVCU+IGRU.*UD1"?%AH?K2[6YLVUZ9KTX65YN_V5F?W=].K!#N'BZ8P_QB& MB<9JZ-L8Z :HR6WBJHF3XZD02[;Z05 ^UJ!)]2J1U]WZY741Z@ (?WT1!T62 MKLK(KE0S+UC>7\M_Y8 U>F)3ILEF4JC^RAXE.!C% _3.3/$0H1J65';SV/DP*,2W<7M\B+S:Z=(VHO<['$%A JVBR86*/E; M)=O>RLY[.GQY7PB8#LDJE;9.3NS)9-)!&V'&ROU>@"ZQDJ1;OH##4@\.IK/M M+?(&>-Z&U1P49,CE-.RLSN>$1DXS$*]+VY$*F&*.ED18NU,0O)#B!1>VU)9U M(216H].FRF6G)5[I@P-THHH>SBB0\--4(>?C>B3],A2I90IR";*$Z$X@!U", MITK<4@;3/*ZE=JX/LS?V^ UX)F2+<#:EJ#MIJ5'/8PMEA2D[.5BEJSO-$\FZT ?IQYZM.*IYT[=I"P:D)+'!>-SL0$BLDVBV7:0ES-9;, M(LITY6$0_43JE!*TYU:NHDE5Z,D0N*'A%(3-0[&%^;?):+S +&&T, J;BZ:] ML]+ZJYE?F!@?2;WAD.9Y'('K46G<*A9,K H?7B.8=+CD<$D36.)D6@DQ'!'> M7UB,EX-==.JY)1(3<7QP)4VG-*O(*IU%I75JT:RJ@.,#6CQAH43ZZ7,3#*M))<%Y1WPVQX(3//KZ> =IY<$$AI M#>T>8&%*X\V<&:XL">8S7%['82[(NK&@W@,2QK<^%#\/&2S%?83!X/183B^D MS$,OP@W7"23L8>9*U<5?$ V_;T""!+Z[][..?5U7DQV#,,"H^/8A!F#*UBCH MQF344J[#VE+09 R*KR8I330BY>]ID'%5POK,67HKB+:_E)E<0.CZ"&Z-8I/R)8(9>;K/L =/41!2="6=47?D0J"N5A\M1A]FR"'Q@4R3SD''G M#CG'#8-6 GZMY(K/S27!+<-+;U5$J"%\6ZJ4Z!+E8A1\3#(O? +=^>$5,7P: M\E=X(EQE9U6)3!O"E&%5[:,\)UN[4H6QGKSR%!52J,WW=OO_:%X(G&A'/DCO MU(D 3<:(FS1Y#HN?[_$;E<_;U<\$?D>OY(5<1!?0)&Z)#B3[?!.RJ;%*S?): M1P7EEX2V$D3)*=:EU5B#/*,LDA"--Q#50ZFD M6)LK4")7]V1@$&!E8I4<$**)%9KAT;9[).4ON(G>V3S^H-)Q?1Q"?ZM 'T@' MU3!O=51"V!$?4;]!7S00D8DBYV)E;GXI]W?O$?X.O?P=[F]O:-^'GOE.W09? MZ]K_M9X'T-(T^: _^-A<;I_Q; _6>4R^%OO]1JXWXTUD/'9N+UVEK[OM??#!K?/AN)U@%G[XEP"K_U_CON1<]S/ M-U1]2G^:&/Y6D?ZD\3]02P,$% @ LC!D6$4QAN0H P V@L !$ !Y M;6%B+3(P,C0P,C(Y+GAS9+56VW+:,!!][TS_0?5KQA:&) T$DLEEDF%*FA22 M-,U+1[8%4;$E5Y+!].LK^<;%X )M>9)VSSF[*^W*M,_CP <3S 5AM&/85LT MF+K,(W34,9X&YL7@JMLUP/G9^W= _=H?3!/<$.Q[+7#-7+-+A^P4?$8!;H%; M3#%'DO%3\(S\2%O8#?$Q!U M1IB>1#W4>'6_(G2+G'OOUVO_X-.W<2R#2^@\TN.'V>'DQV-P>4->XC&NU4^^ M'#ZD(=O"?<,! NHRJ.@8NKZLO&G#8GP$Z[6:#5_N>H,$9Z3 5NP3.EX'MYO- M)DR\.;2$C!WNY](-J-T.$KA05EY2@2=42$3=);PG"\(B^ BFSB4H60L]3J$D MAWIX!2>P:XW8!"J'PM<;.3 2Y@BAL /D7 2T) VI(8>U>KVIQLK' :;RAO'@&@]1Y*LL?D;()T."/0-(Q$=8 MZ@X3(7)QE53>HXA2IEI9S5-FT;8P)*I7"X,RZ;MM<>;C1Y4TT LU2VOTM0=> M,?48&(!X'2-=+BCE6AX>$DJ2N-G@V,#48Q+I M4R8;;A*KBL% GLW=.S9!UR M+!0]J:>G#!D_@U1S7>2[D;\7=9Y?%3.SYZ=8.MY\?OIX")*Y:^D.Z1B"Z)?/ MR&QO' \[ACYQ,[_,[ZIL2W50#M$1*N8NN:/5D\H"YQ*(NR65TKN@1%B(N22J MC1>&/TV=2$U_6 @#=!QA /@/*_>1LVOEBH+]_UAR3^N7:VW#Y;%2^]71:ZMR M&9> E@:XZO%,G_T>F3G/U";3KIL-VXJ%-\]TER3F)[!;$CEOCR0V M/.'KXHM-<+W0+=38-NB&3T%ET+4*2Q^./XBAT1FIR26KM.3'&H) M+5HWU3TV[,WI_(F9[,5>3>"RB$H^VZ41%BGY9K_;F'_RM[N(')]>@OX7L&_8 M/;J@''Q="[1AJJ:6OP%02P,$% @ LC!D6'%+E6W]"@ @(8 !4 !Y M;6%B+3(P,C0P,C(Y7VQA8BYX;6S-G5UOX[@5AN\+]#]PW9L6&,<3!RV0[&07 M&4^R,#:;9&//;-M%L: EQA%"DP$E)_:_+RF)LD3Q2$J*DIR+&8_X'NJE^)BD MOHX__;C;4/1"1)IP=CXZ/OHX0H1%/$[8^GST=3&^6,SF\Q%*,\QB3#DCYR/& M1S_^\.<_(?GGTW?C,;I*"(W/T!<>C>?L@7^/;O"&G*&?"","9UQ\C[YANE5; M^%5"B4 SOGFF)".RH-CQ&?K[T?1XA<;C ?5^(RSFXNO]O*KW,T[/)Y/7U M]8CQ%_S*Q5-Z%/'-L H7&+'T;)$7H""FEY -LUVFCKC)HXMKL'1$)CR_9^UR;T9[L MR^^.R/Z'!M3CG3=AR3-,WV6^'NG<]@UYWQ$_Q+D_TG*<)^\[TK7(_XOMK&WY MS8?7?ERIVG@M/S4LDETF)S 2:Y.JBHX1.-]#/C&4=5>U\ZA1+U6C.1?MMJN9 M,:\S)='1FK],8I+(NJP8Q@"]ZZ&_T[8Y%UC%04 SQ"$X6]2#4!7E MB:,+QK:8WI-G+KKP:)SPMVUW\5.)@$3(=#J0H#T,JSA-)M=L0/0RUE*[I :R:W!BRH(BQ M>P-9*>0HU_N'Y)+%@Q"I='X ,6S:\2A% <+1=-:'AE3[!.,J22-,"R]70-4#S-0)I[N9KM9$6%I7%OBB@W(G&;"+ ^"!<"4R4 A0TJ'"J&7GM=W"5BF'F($FV/* MW!)@-]FDH*D)B 2K,8"&@S9_IM0+$3,Y,@E,YRPFNY_)'FQ72^>6"FQW60&$ >$3K=#@" 9A)I1/D&:LXB+ M9UY[W&'&MW( W,]X#*]0>J+<0C6H"4VT.D," FR(3P"S1NB'XID4Q-5[/'D% M2-7@A;B+.)8'*BW_N4X8.0;;;]6ZI:O#;I,IBS @DF!W #^E\H/^@%0,NF6A M0#-]0U.G_J&9#H5F&C0TT_= LWSE@4!S\H:FGOB'YF0H-"=!0W/R+FADQWL= M:V;RXZU8\E?;P]F@T@LR;:M68 ZR\'!I>>N#106H]8P*\8E)OK"Z%7>"OR0L M@I?,D-P+,(!I*S6&-CQT[ ;[^*D6Q#K.ZUA3+,I[OR1:YF>4:9JT#S&%)CQ( MFL9Z!Y="[1.).YYFF/X[>>X\$;>+O>!A-6R%I*$,#Q6;O3Y@BA@D@WR<6)>X MJAL:UE?)C')WKP!;;!U> :X5!@&!S5'[%>#BZDDABY#N<[3U7B582*U#]^U,F; M+2OO\MB>&P1TKGJYTZ;N<:LHB-[O( M$V2R%ZHBT"=;"Q)MY?RX/YZNEDE&;2>7;8FS.0DP5\U(1GD0; "F3!;R,L0? MT/'TKZN_(1WEN/MO^%)@E3QVL=^L. 6R3UE5KB#HL*@YL$B"0 'V9=)PPU$I M18761W:JAEE+FN;Q0&T>DV1ZTO?Z.O/0WYE[OH49HBP L)=IGK MH=]FTAS^ZYH@$.@PUCHI*:5(:WV\D'"8LM;]BX"UMT7 NF<1L YQ$; >N@A8 M>UL$Z-T6*4+DN'2[HLD: \D).]6NH>BP;/)AD0:%"NP/'#.J$'2(<9W1,D]Q MIM+SBTV^_ROYP=)*0.8J89A%":95>D3;%?'^$&>T##1?@=.C#X.A829;.!5A.I=A%7A(=>GZ4GKQ M ,9OA-*?&7]E"X)3SDA<7$NQW2GJUKM]8J;'=O.A&4 T"ZR M1U2+K.)WA\ &0G+'KVMWFC;>VK9J V*FTR#T#G>9\^.P-BZB/+UBF1'U>Q') M"_F",UQZ ]L+R5V_5-EEVGR;TJ8-"*%.@^#[DU6,2A6#-5/>4L:(F5QJK7G' M4^*&RGWBF);%=NZ82A(0'C9?'1ED!-):+RPL-IC2S]LT822%)R)#Y98%J\4F M"PU)0"S8? $LY%*DM5Y8N-P0L9;3VT^"OV:/97Y6L&V VBT;G9:;C%BE ;'2 MY0]@1H>@(D:GU/4#S^Z04+S(L@BWU")UC UHUF"FI0L)&,AUCRYS@.1BO29S:B>W!Y>XC5$CE?&%H/&PKBF"((1T!:T+*[_5H"?W'G; M%4VB*\HQ?)6EH7&<,:]MSTB6=Q $1$#;%90B+Q>B7.FE_S]C]B2VSUFTOQ,\ M(D0]9956HU7?];>!T6Z9>5.3FC0-"@V(L[?X!0@\5(%J=7RHS5@^+^:IA\95 M-C<>/2T>L3R M]LL53.H- 9?!>\,>@' M5 2C6K2G\[/TD 60Q)_W]^2!"/7>P9+LLL]R1T\=9Q@#8EV?O0UNCGDRUQL8 M!(1O=0N=ZJ6H7@%:J6?$RBK0[ZH2E-=B^_WR^J9K^4ENUIOD7RN<$KGEOU!+ M P04 " "R,&18!V8I)U,' #/5P %0 'EM86(M,C R-# R,CE?<')E M+GAM;,V<77/:.!2&[W=F_X.7O28$Z'XD3;:3T-!AFC;9D+:[>],1M@!-9(F1 MY #_?B4;4SXL^>3&)[E(B'GU\3['EGULR1?O5BF/GJG23(K+5O?DM!51$C$:M2!LB$L*EH).:VR"'C5$4#F2XX-=1^431\'OUVTNM.HG8; M4.]7*A*IOCR,MO7.C5GH\TYGN5R>"/E,EE(]Z9-8IK *QX:83&]K.UV=;GZ* MXA>Z6FW\\^GVW$\IREI,^&X MQ;15EG*U5)7KGIV==?)O2^F1:':N\^[=RIB8 M/.RUS41>A?NO7:*3B];3F&K[KTY[?7.7,6_[HG,>F'W2LW<3M6*.GN-+A35 M5)C$KHS=EVA25N3:!W7+,..4F]VD&[7=/I6EMB'[L5!N>E'V@\MX MKVGNV,L#G^5^G!/6-#Z9R>=.0IDEW>N[#PY"/P=@__F>-W0UT4:1V)0U<3*A M/*__N]4<2#H-]*HD\6AKK.[4ON*P3[L1NU)Q)%5"E65=UD54O!>GXUURH^@L MB+(5M>,YX]L03Y5,?70V)*2GH[N@;!/-T+RR[2>N#T-.9M4X#R1 GET,H)5N ML(B^ISI6;.&XU(#=4P+Y]E#Y5GAK&'-Y[#S0&7/]=5UQ)UKJ-H;'!4\1(/@^ MYD@1=(L4@2LA,L(?Z$*J&O#[2B#O-YB\J[PA8?X[(\I0Q=<0TD=B(.S?,&%[ M'"+Q?E1$:.;X0( ?JX'$?T>]\/!X1$(^GE/.7?)&!&@OK](#L?^!B=WO\Q6 MOWEVYW=[:H&SWRD"Q/_G:\%_Y!8I O=4,9G84[H"L#\2 ZF?85+W.$3E?2,2 M*.VM%)S_X,,^L(>$>LAT3'C1HZ'=IL.X*^10Y"@Y9ZU-5.S_4J+ T'?$4.0H M:6B-Q8:!#S*E]CH3'%7\:BARE 2TSF3#S&^$86;M[O9_SM+)CQNG^ZR/55#& M*$FGSQ0*V_).@S#N(4:([Z$2RA@EUPR90^$\L'X4X2.1T-5'N@Z!/I)"2:/D MF$%[**CO%4N)6H]97#]H'&NAL%$RR[!!%-J/9#5*K"LV9<5CP'KHWB)0]BAI M)<@N2@A&(I9J(7=N%P]D9H_']4 FP2&]IB T'"CYY@NLHP3E*DDL+KWY<\L$ M[89"42D'/R/""T# YBO!WGL9]AX<.TH>6FOSE6#OOPQ['XX=)1>MM8F)?6 _ MWJE'N?0\@?:*H&;2G0@ M@?)%R54K[32-U$584>+???<54* H"6B5F89YWDKW[&,N1?!^[+$*RA4ED_29 M:GK@=;.(M??0W_D:/(,-95@]M-$PQF^*&=N#@4S33&SNT7B>BGFD4+PHZ5_0 M7L.HQY*SF!DF9I_L%:)BA%=SKM)!(:,D>WYC#1.^5]1%FMK+[GP>EUMFH.ZF M4]_(&])#B:/D>O5&<BG_BE+0**"D?5#338\S-,[LL+?N]B:/;L6, M9Y0Y4D%9HZ1\/E,-L_TL'Q5QJ_3&ZW0BN7]Y2*402A@EP0M8:QCR7C^J\1Y( MH&!1,KM*.TACPLTJGA,QH_[9"]5**&"43"]D#FWLG8'&WMD+QUZ4C,]G"HEM M,3?<'E%W$\YFQ+^2+%@ O,X&DWC :M/K]_(E/V[]MDKS?@SMAVKL'BD4.,X2 MR9"]IE%G"3,T*;HT9(*(V*94VW5MGNR\OA0T #AK*(&F46[O?Z.XM HX#X#+'&+DH(ODJ>64HJGPBJ/,> 1PI%COCLT&,/9^YE M,:EY>^XI7M01(NXK 06/^! Q;!9I?IJAKL_LF;XGAFQZ&.+O*P'EC_A ,6P6 M;?Z\&M@3STR&GYD?"*&T$:?"5EI#@3Q.">?7F6:"ZN#8&K=TT%Y(R:F5<9PUDQE$\[B(9%V^)X/R182,9/X[DU MK>\RD[^WU/8O>-,@6 X:&LQ%G #C2%=!^L="+YI&1KLRU;>@I M?%$$* Z-#^H;A< 8*L)TT3GR=6LWN#?3%M^X7^[MJW;+_U!+ 0(4 Q0 ( M +(P9%B8>^AKLA< .AZ 1 " 0 !T;3(T-S$7 !T;3(T-S6UA8BTR,#(T,#(R.2YX M6UA8BTR,#(T,#(R.5]L86(N>&UL4$L! A0#% @ LC!D6 =F*2=3 M!P SU< !4 ( !?#8 'EM86(M,C R-# R,CE?<')E+GAM 7;%!+!08 !0 % $ XML 17 tm247768d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001722964 2024-02-29 2024-02-29 iso4217:USD shares iso4217:USD shares false 0001722964 8-K 2024-02-29 Y-MABS THERAPEUTICS, INC. DE 001-38650 47-4619612 230 Park Avenue Suite 3350 New York NY 10169 646 885-8505 false false false false Common Stock, $0.0001 par value YMAB NASDAQ false